U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Cover of Drugs and Lactation Database (LactMed®)

Drugs and Lactation Database (LactMed®) [Internet].

Show details

Baricitinib

Last Revision: July 18, 2022.

Estimated reading time: 1 minute

CASRN: 1187594-09-7

image 162108950 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of baricitinib during breastfeeding. Most sources recommend that mothers not breastfeed while taking baricitinib. An alternate drug is preferred, especially while nursing a newborn or preterm infant. The manufacturer recommends that women avoid nursing during therapy and for 4 days after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Rheumatoid Arthritis) Adalimumab, Certolizumab Pegol, Etanercept, Infliximab, Tocilizumab

Substance Identification

Substance Name

Baricitinib

CAS Registry Number

1187594-09-7

Drug Class

Breast Feeding

Lactation

Milk, Human

Antirheumatic Agents

Enzyme Inhibitors

Janus Kinase Inhibitors

JAK Inhibitors

Signal Transduction Inhibitors

Protein Kinase Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Copyright Notice

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Bookshelf ID: NBK525499PMID: 30222291

Views

Related information

Similar articles in PubMed

  • Identification, Synthesis, and Characterization of Novel Baricitinib Impurities.[ACS Omega. 2023]
    Identification, Synthesis, and Characterization of Novel Baricitinib Impurities.
    Vaddamanu G, Goswami A, Reddy NRS, Kumar Reddy KRV, Mulakayala N. ACS Omega. 2023 Mar 14; 8(10):9583-9591. Epub 2023 Mar 2.
  • Review Upadacitinib.[Drugs and Lactation Database (...]
    Review Upadacitinib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Fedratinib.[Drugs and Lactation Database (...]
    Review Fedratinib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Ruxolitinib.[Drugs and Lactation Database (...]
    Review Ruxolitinib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Abrocitinib.[Drugs and Lactation Database (...]
    Review Abrocitinib.
    . Drugs and Lactation Database (LactMed®). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...